Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside.

Abstract

Eighteen patients received 1,250 mg of allopurinol riboside (AR) four times daily for 28 d. Nine of the patients concurrently received 500 mg probenecid (PB) four times daily. Cure was assessed clinically and parasitologically. Patients who had culture-positive and nonhealing lesions 3 mo after therapy received pentavalent antimony. Of the nine patients who received AR alone, four (44%) had clinical improvement at the end of therapy and two (22%) were culture-negative. A third patient became culture negative at 2 mo after therapy. The culture-negative patients were completely healed at 1 mo and remained so at 1 y after therapy. Of the nine patients who received AR plus PB, four had complete healing and two had clinical improvement at the end of therapy; however, all patients remained culture-positive. At 2-3 mo after therapy, six (67%) of the patients were completely healed, and of these, five (56%) were culture-negative. The drug was well-tolerated.

• Authors: R E Saenz, H M Paz, C M Johnson, J J Marr, D J Nelson, K H Pattishall, M D Rogers
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 160 Issue 1 Pg. 153-8 (Jul 1989) ISSN: 0022-1899 [Print] United States
• PMID: 2659681 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiprotozoal Agents
• Ribonucleosides
• Allopurinol
• Probenecid
• allopurinol riboside

Topics

• Adult
• Allopurinol (analogs & derivatives, pharmacology, therapeutic use)
• Animals
• Antiprotozoal Agents (pharmacology, therapeutic use)
• Biopsy
• Clinical Trials as Topic
• Drug Therapy, Combination
• Humans
• Leishmania braziliensis (drug effects)
• Leishmaniasis (drug therapy)
• Male
• Middle Aged
• Probenecid (pharmacology, therapeutic use)
• Ribonucleosides (pharmacology, therapeutic use)
• Skin (parasitology)